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Introduction
Dihydropyrimidinase (DHP [enzyme commission 3.5.2.2]), also known as 
5,6-dihydropyrimidine amidohydrolase, is the second enzyme in the three-step catalytic 
pathway of pyrimidine uracil and thymine. It catalyses the reversible hydrolytic ring 
opening of 5,6-dihydrouracil and 5,6-dihydrothymine and converts them to N-carbamyl-
β-alanine and N-carbamyl-β-aminoisobutyric acid, respectively. The enzyme is almost 
exclusively expressed in liver and kidney as a major 2.5-kb transcript and a minor 3.8-kb 
transcript.1 The human DHP gene, DPYS, has been mapped to chromosome 8q22 by 
fluorescence in-situ hybridisation, and consists of 10 exons spanning more than 80 kb in 
the human genome.2
 Dihydropyrimidinase deficiency (MIM 222748) is an autosomal recessive inborn error 
of pyrimidine metabolism characterised by the presence of dihydropyrimidinuria. The first 
case of DHP deficiency was first reported by Duran et al.3 The patient was a Turkish male 
infant presenting with convulsion at 8 weeks after birth; at age 19 months the child appeared 
to be normal.3 Up till now, this disease has been reported in over 20 patients with a variable 
clinical phenotype. Most DHP deficiency patients present with neurological disturbance, 
ranging from developmental delay,4 mental retardation,4,5 seizures,3-5 hypotonia,5,6 autism,5 
and a neurodegenerative clinical course.6 Other presenting features included dysmorphic 
features,6,7 growth retardation, failure to thrive, and a variety of gastro-intestinal problems.5,8 
On the other hand, DHP deficiency has also been reported in asymptomatic individuals.9-11 
In this case report, we describe the clinical, biochemical, and genetic findings of the first 
Chinese case of DHP deficiency.
Case report
Our patient was a 32-month-old Chinese boy born to healthy non-consanguineous 
parents. He was born at full term by elective caesarean section. His birth weight was 3.47 
kg and his Apgar scores were 8 at both 1 and 5 minutes after birth. His postnatal course was 
unremarkable except for a transient period of neonatal jaundice beginning on day 3, and 
the peak bilirubin level of 254 μmol/L, the level readily normalised after phototherapy. The 
patient was referred to Department of Paediatrics, Tseung Kwan O Hospital in January 2011 
for delay in language development. At the age of 2 years, he still could not produce a single 
recognisable word. Motor development was appropriate for his age. Socially the child 
showed poor eye contact, but no restriction of other interests or ritualistic behaviour. On 
physical examination, his weight was at 75th centile, his height at the 97th centile, and his 
head circumference was in the 25th centile, all of which were normal and there were no 
dysmorphic features. Neurological examination yielded nil abnormal. Routine blood test 
showed that his complete blood picture, renal function test, blood gas, random glucose 
and ammonia levels were not abnormal. Liver function was unremarkable except for a 
mildly elevated alanine aminotransferase level of 78 U/L. Magnetic resonance imaging 
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Dihydropyrimidinase deficiency is an autosomal recessive inborn error of metabolism 
characterised by the presence of dihydropyrimidinuria. Its clinical presentation is 
variable and has also been reported in asymptomatic subjects. We report the first case of 
dihydropyrimidinase deficiency in Hong Kong, which is also the first reported in a Chinese 
subject. The patient was a 32-month-old boy who presented with language development 
delay. Biochemical analysis confirmed markedly increased urinary excretion of dihydrouracil 
and dihydrothymine, whilst DNA testing confirmed that the patient was compound 
heterozygous for two missense mutations, one known (p.R302Q) and the other was novel 
(p.N16K).
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二氫嘧啶酶缺乏症指新陳代謝出現常染色體隱性先天性障礙，其一特
徵是出現二氫嘧啶尿症。它的臨床表現多變，過去也有出現於無徵狀
患者的病例。本文報告香港首宗二氫嘧啶酶缺乏症病例，也是華人首
宗病例報告。患者為32個月大的男童，因語言發展遲緩入院。生物化
學分析證實二氫尿嘧啶和二氫胸腺嘧啶的泌尿排泄明顯增加。DNA測
試證實患者的兩種基因複合雜合錯義突變：已知的p.R302Q和新型的
p.N16K。
二氫嘧啶尿症華籍男童確診二氫嘧啶酶缺乏症
of the brain yielded no abnormality. Biochemical 
investigations for suspected inherited metabolic 
disease were performed. Urine organic acid analysis 
by gas chromatography–mass spectrometry showed 
markedly increased excretion of uracil, thymine, 
dihydrouracil, and dihydrothymine (Fig 1). Notably, 
β-alanine and β-aminoisobutyric acid were not 
detected in the urine amino acid analysis. Plasma 
amino acid analysis showed a normal pattern.
 In view of biochemical diagnosis of DHP 
deficiency, genetic testing for DPYS mutations 
was performed on the patient and his parents 
after obtaining parental informed consent. The 
nine coding exons and flanking intronic regions 
of the DPYS gene were amplified by polymerase 
chain reaction (PCR) on the subject’s genomic 
DNA from peripheral blood specimens, and direct 
sequencing of amplification products performed 
in both the forward and reverse directions. The 
PCR-amplified fragment sequences were compared 
with NCBI Reference Sequences, NG_008840.1 and 
NM_001385.2. Two missense mutations were found 
in the proband’s DNA, a novel c.48C>G transversion 
that changes asparagine to lysine at codon 15 in 
exon 1 (p.N16K), and a c.905G>A transversion that 
changes arginine to glutamine at codon 302 in exon 
5 (p.R302Q) [Fig 2]. Each parent was heterozygous for 
one of these two mutations (N16K in the mother and 
R302Q in the father), indicating that the proband is a 
compound heterozygote.
Discussion
Deficiency of DHP is a rare inborn error of the 
pyrimidine degradation pathway, with only around 20 
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FIG 1.  Chromatogram of urine organic acid analysis showing markedly elevated levels of uracil, thymine, dihydrouracil, and dihydrothymine in urine
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patients having been reported in literature. In a study 
by Sumi et al,11 after analysing urine samples from 
21 200 healthy Japanese infants, two asymptomatic 
cases of dihydropyrimidinuria were encountered. 
The authors suggested that in Japan, the estimated 
prevalence of the deficiency was approximately 
1/10 000.11 The clinical phenotype of patients with DHP 
deficiency is highly variable. Notably, this disorder 
has also been reported in asymptomatic individuals 
identified by population screening for pyrimidine 
metabolism disorders9,10 or family screening of 
relatives of DHP deficiency patients.5,11 Furthermore, 
it has been demonstrated by family studies that 
siblings who shared the same DPYS mutations as the 
clinically affected index patient can be asymptomatic, 
suggesting that additional environmental factors may 
be involved in triggering the clinical phenotype. Also, 
a direct causal relationship between the genetic and 
biochemical changes in DHP deficiency and various 
clinical phenotypes, such as developmental delay as 
in our patient, cannot be definitively proven. This 
information too should be conveyed to the patient’s 
parents during genetic counselling. 
 The pathophysiological mechanism of the 
various clinical features of DHP deficiency is not 
completely understood. The pyrimidine metabolic 
pathway is involved in the biosynthesis of both β-
alanine and β-aminoisobutyric acid; the former was 
a structural homologue of γ-aminobutyric acid and 
glycine, and the latter a partial agonist of the glycine 
receptor. Thus, pyrimidine metabolism is implicated 
in regulating neurotransmission in the central 
nervous system, and it has even been postulated 
that a decrease in β-alanine and β-aminoisobutyric 
acid may be responsible for the neurological 
manifestations of DHP deficiency.12,13
 Our case was found to have compound 
heterozygote for mutations c.48C>G (p.N16K) 
and c.905G>A (p.R302Q). Analysis of the crystal 
structure of human DHP showed that the point 
mutation p.R302Q prevents oligomerisation of DHP 
subunits and formation of an enzyme homotetramer. 
Functional analysis has also confirmed that mutant 
DHP enzymes containing the p.R302Q have only 3.9% 
residual activity.5 The other mutation c.48C>G (p.N16K) 
was novel and changed a highly evolutionarily 
conserved asparagine to lysine at codon 16. We 
have performed a DPYS gene study on 150 ethnically 
matched normal control subjects, in whom this 
mutation was not found. Also, computational analysis 
using PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/), which predicts damaging effects of missense 
mutations, indicated that this novel mutation was 
‘probably damaging’ with a score of 1.000 using the 
HumDiv dataset. All these findings suggest that the 
novel mutation c.48C>G (p.N16K) is damaging to the 
DHP enzyme function.
 Currently, no specific treatment is available 
for DHP deficiency. However, identification of this 
disorder is crucial, because patients with inborn 
FIG 2.  Direct sequencing chromatograms of DPYS sequence alterations in exon 1 and exon 5
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error of pyrimidine metabolism cannot metabolise 
fluoropyrimidine chemotherapeutic agents, such as 
5-fluorouracil (5-FU) and its prodrug capecitabine. 
It has been reported that partial-to-complete 
deficiency of dihydropyrimidine dehydrogenase (the 
first enzyme in the three-step pyrimidine catalytic 
pathway) accounted for up to 43% of patients with 
5-FU–related toxicity.14 The contribution of this 
deficiency in 5-FU toxicity has also been increasingly 
recognised. In a case report, severe 5-FU toxicity 
was attributed to a partial deficiency of DHP due 
to heterozygous missense mutation in DPYS gene, 
which illustrates the importance of identifying not 
only DHP deficiency patients, but also carriers.15 
Dihydropyrimidinase deficiency should be regarded 
as a model of how knowledge in pharmacogenomics 
translates to improving clinical outcomes by reducing 
serious adverse drug reactions. 
